Intra-Cellular Therapies prices $500M public offering of 6.85M shares at $73.00 per share

Intra-Cellular Therapies, Inc.

Gross proceeds of $500M from 6,849,316 shares at $73.00/share; net proceeds ~$472.1M after underwriting discounts and expenses.
Underwriters granted 30-day option to purchase up to 1,027,397 additional shares on same terms.
Offering expected to close April 22, 2024; J.P. Morgan, Leerink, BofA, Morgan Stanley, RBC acting as joint book-runners.
Company is selling all shares; no specific use of proceeds disclosed in the filing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Intra-Cellular Therapies, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Leerink Partners LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein valued at approximately $472.1 million (effective 2024-04-17).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC, Leerink Partners LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein
Value: approximately $472.1 million
Effective: 2024-04-17

Exact text from the filing

On April 17, 2024, Intra-Cellular Therapies, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Leerink Partners LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), relating to an underwritten public offering of 6,849,316 shares (the “ Underwritten Shares ”) of the Company’s common stock

View on SEC.gov

Browse all material agreements →

Source: SEC EDGAR

accession 0001193125-24-100960

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.